Adsorbed Purified Pertussis Vaccine
Ovarian Serous Adenocarcinoma
Explore 90 assets in Ovarian Serous Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06639074CT.gov Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adsorbed Purified Pertussis Vaccine (this asset) | Mayo Clinic | P2 | CCC · 53 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Adsorbed Purified Pertussis Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Serous Adenocarcinoma | — | P2 | CCC · 53 |
| Fallopian Tube Carcinoma | — | P2 | CCC · 53 |
| Ovarian Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adsorbed Purified Pertussis Vaccine in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adsorbed-purified-pertussis-vaccine-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →